Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

64.56 USD +0.38 (+0.59%)
Official Closing Price Updated: 7:58 PM EST, Jan 22, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 9,071,800
Open 63.89
Bid (Size) 64.25 (1)
Ask (Size) 64.78 (4)
Prev. Close 64.18
Today's Range 63.76 - 65.03
52wk Range 45.76 - 67.80
Shares Outstanding 1,634,538,458
Dividend Yield 2.48%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
U.S. Food and Drug Administration Approves OPDIVO® (nivolumab) in Combination with CABOMETYX® (cabozantinib) as First-line Treatment for Patients with Advanced Renal Cell Carcinoma
US FDA Approves OPDIVO in Combination with CABOMETYX as First-line Treatment for Patients with Advanced Renal Cell Carcinoma 
From Business Wire News Releases
Bristol Myers Squibb Announces Earnings Call Time Change; Fourth Quarter 2020 Earnings Call to Occur on February 4, 2021 at 10 a.m. (Eastern Time)
Bristol Myers Squibb Announces Earnings Call Time Change; Fourth Quarter 2020 Earnings Call to Occur on February 4, 2021 at 10 a.m. (Eastern Time) 
From Business Wire News Releases

Performance

YTD
+5.18%
+5.18%
1 Month
+5.84%
+5.84%
3 Month
+7.37%
+7.37%
6 Month
+11.60%
+11.60%
1 Year
-3.45%
-3.45%

More News

Read More
U.S. Food and Drug Administration Accepts for Priority Review Application for Opdivo® (nivolumab) Combined with Chemotherapy as First-Line Treatment in Metastatic Gastric Cancer, Gastroesophageal Junc
From Business Wire News Releases
U.S. Food and Drug Administration Accepts for Priority Review Application for Opdivo® (nivolumab) as Adjuvant Therapy for Patients with Resected Esophageal or Gastroesophageal Junction Cancer
From Business Wire News Releases
Interesting BMY Put And Call Options For March 5th
Tags Stocks
From Market News Video
Exelixis Gets FDA Approval for Cabometyx in Combination Therapy for Front-Line RCC
Tags EXEL Market News BMY
From Motley Fool
Notable ETF Inflow Detected - VIG, PEP, UNP, BMY
Tags ETFs
From ETF Channel
Bristol Myers Stock Is Eyeing A Buy Point At A 5-Year High — Is It A Buy?
From Investor's Business Daily
2 Unstoppable Stocks to Buy With $1,000
Tags PINS Market News SNAP
From Motley Fool
Soap Opera
Tags Stocks / Equities
From Blogs - TalkMarkets
Piclidenoson From Can-Fite Biopharma Shows New, Promising Developments For Psoriasis Treatment
Tags News JNJ General
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.